Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122804 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL31616404 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL563252 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL30724855 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL1491293 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL18237339 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL18089434 | 1.00 | TSHR (0.40) | TSHR | |
| Hydrochloric Acid SCHEMBL25375836 | 0.97 | TSHR (0.39) | TSHR | |
| SCHEMBL2818899 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL25377147 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316249-A1 | INJECTION FORMULATION COMPOSITION FOR USE AS FILLER OR DRUG CARRIER THROUGH CLICK CHEMISTRY REACTION | Ajou University Industry-Academic Corporation Foundation (KR) | 2024-09-26 | — | — | US | claimed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250333696-A1 | DNA-CHIMERIC ANTIGEN RECEPTOR T CELLS FOR IMMUNOTHERAPY | UNIV ARIZONA STATE (US) | 2025-10-30 | — | — | US | disclosed |
| US-12441751-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | PAUL SCHERRER INSTITUT | 2013-07-25 | — | — | US | disclosed |
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092983-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
| EP-2558538-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Oligasis (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012058635-A1 | BIOTIN DERIVATIVES | Life Technologies Corporation (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2011130694-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130694-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2009139863-A2 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | TSHR 1151/4885 |
| US-12441751-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | TSHR 3743/4885 |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | TSHR 389/4885 |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | TSHR 2184/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | TSHR 3232/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | TSHR 1235/4885 |
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | SGMS2, SGMS1, DEGS1 | TSHR 1252/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TSHR 1510/4885 |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2BP2 | TSHR 3904/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | TSHR 1034/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | TSHR 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.